Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232709 | 0.81 | GAA (0.43) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL5274704 | 0.81 | GAA (0.43) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10910425 | 0.81 | GAA (0.46) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1847963 | 0.81 | GAA (0.43) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL5276732 | 0.80 | GAA (0.42) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12232688 | 0.79 | MEN1 (0.44) | GAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2543782 | 0.79 | GAA (0.41) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL13334678 | 0.79 | GAA (0.41) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL5276735 | 0.79 | GAA (0.41) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL18825530 | 0.79 | CYP3A4 (0.46) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946144-B2 | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20100113333-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. (CA) | 2010-05-06 | — | — | US | disclosed |
| US-20080287396-A1 | Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections | TARGANTA THERAPEUTICA INC. (CA) | 2008-11-20 | — | — | US | disclosed |
| US-20080287396-A1 | Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections | TARGANTA THERAPEUTICA INC. (CA) | 2008-11-20 | — | — | US | disclosed |
| EP-1881974-A2 | PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Inc. (CA) | 2008-01-30 | — | — | EP | disclosed |
| WO-2007017762-A2 | PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113333-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | PGLS, BPGM, PAG1 | GAA 673/4885CYP3A4 4566/4885CYP2C9 4362/4885 |
| US-20080287396-A1 | Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections | BPGM, PSPH, PGLS | GAA 1879/4885CYP3A4 2952/4885CYP2C9 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.